Blood-thinning drug may be harmful post-COVID-19
The Heal-COVID trial, conducted in the UK, found that the
anticoagulant apixaban is not indicated for patients recovering from severe
SARS-CoV-2 infection, and it may actually contribute to major bleeding, leading
to a call for its use to be discontinued in these patients. Investigators said
the drug does not help prevent hospital readmission or death, and it could put
patients at risk without providing any benefit.
Full Story: The
Guardian (London) (11/28)
No comments:
Post a Comment